1. Volume 56, Issue 2, Pages 392-394 (August 2009)
Reduction of Serum Prostate-Specific Antigen Levels following Varicella-Zoster Infection and Valaciclovir Treatment in Prostate Cancer 
Roy R. Jurhill, Haitze van der Veen, Geert J.L.H. van Leenders, Paul C.M.S. Verhagen 
European Urology 
Volume 56, Issue 2, Pages (August 2009)
DOI: /j.eururo
Copyright © 2009 European Association of Urology Terms and Conditions

2. Fig. 1
Patient A: Prostate needle biopsy showing a Gleason 3+4=7 prostate carcinoma.
European Urology  , DOI: ( /j.eururo )
Copyright © 2009 European Association of Urology Terms and Conditions

3. Fig. 2
Patient A: Prostate-specific antigen (PSA) levels and events. Note the decrease in PSA by 1.2μg/l after varicella-zoster virus (VZV) reactivation and valaciclovir (vACV) treatment.
European Urology  , DOI: ( /j.eururo )
Copyright © 2009 European Association of Urology Terms and Conditions

4. Fig. 3
Patient B: Prostate needle biopsy showing a Gleason 3+5=8 prostate carcinoma.
European Urology  , DOI: ( /j.eururo )
Copyright © 2009 European Association of Urology Terms and Conditions

5. Fig. 4
Patient B: Prostate-specific antigen (PSA) levels and events. Note that PSA has remained <0.01μg/l since the varicella-zoster virus (VZV) reactivation and valaciclovir (vACV) treatment.
European Urology  , DOI: ( /j.eururo )
Copyright © 2009 European Association of Urology Terms and Conditions